Diffuse large B-cell lymphoma (DLBCL) includes at least two different subtypes according to cell of origin (COO): germinal center and post-germinal/activated (ABC), with the latter showing poorer outcome probably due to constitutive NF-κB antiapoptotic pathway activation. MYD88 mutations were first described in 39% of DLBCL, basically restricted to ABC subtype as gain-of-function mutations resulting with increased NF-κB activation. In the present study we show that MYD88 L265P mutations are seen mostly, but not exclusively, in ABC subtype whereas other variants do not present COO preference. In addition, the poor prognosis of MYD88 mutations is restricted to L265P but not to other mutations that show even a better outcome than wild type MYD88. However, the clinical impact of MYD88 L265P was not independent from COO. In conclusion, knowledge of MYD88 mutational status could be useful in the management of DLBCL patients with the future introduction of drugs targeting TLR/MYD88 pathway. L265P and other variants was 62%, 52% and 75%, respectively (p=0.05). IPI (HR=2.71; p<0.001) and MYD88 L265P (HR=1.786; p=0.023) were independent variables predicting OS in the multivariate analysis. However, MYD88 L265P lost its independent value when COO was included in the model.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in terms of morphology, immunophenotyping, gene expression profile (GEP), oncogenic aberrations, clinical presentation and outcome (1) (2) (3) . Two major subtypes related to the different cell of origin (COO) of the tumor have been distinguished according to GEP:
germinal center B-cell like (GCB) and activated B-cell like (ABC). Each lymphoma subtype bears a phenotypic resemblance to B-cells at a particular stage of differentiation (known as COO). The germinal center B-cell is the normal counterpart of GCB subtype whereas ABC subtype resembles post-germinal center plasmablasts (1, 4, 5) . In addition, they are associated with distinct genetic lesions and oncogenic pathways in tumor development (2, 6, 7) . GEP studies have shown that the unfavorable prognosis of ABC DLBCL subtype most likely relies on the constitutive activation of NF-κB transcription complex blocking apoptosis (7) (8) (9) (10) (11) . A variety of signaling pathways are capable of inducing NF-κB transcription complex, including Bcell receptor (BCR), CD40 and Toll-like receptor (TLR) (8) (9) (10) (11) (12) (13) (14) . Oncogenic CARD11, CD79A/B and TNFAIP3 (also known as A20) mutations activate NF-κB by BCR signaling. Inactivation of TNFAIP3 can activate NF-κB downstream of other pathways besides BCR signaling. Moreover, myeloid differentiation primary response gene 88 (MYD88) mutations may activate this pathway through TLR signaling (8) (9) (10) (11) 15) .
MYD88 is an adaptor protein of the Toll-like and interleukin-1 receptors that participates in the innate immune response and plays a crucial role in the homeostasis of human B cells (16) . After TLRs activation MYD88 is phosphorylated and subsequently recruits IL-1R-associated kinases (IRAKs) and other downstream proteins such as TRAF6 resulting in NF-κB, JAK kinase / STAT3 activation and secretion of IL6, IL10 and interferon-β. Ngo et al. described that about 39% of ABC DLBCLs had MYD88 mutations whereas they were rare in GCB cases (11) . MYD88 has also been recurrently found mutated at different frequencies in several lymphoid Author Manuscript Published OnlineFirst on January 20, 2016; DOI: 10.1158/1078-0432.CCR- neoplasms including the majority of Waldenström macroglobulinemias (90%), in 69% of primary cutaneous leg type DLBCL, in 38%-50% of central nervous system lymphomas, in 9% of MALT lymphomas and in approximately 3% of patients with chronic lymphocytic leukemia (CLL) (11, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . MYD88 L265P mutation is the most frequent and most oncogenic form in DLBCL, although a gain of function triggering an increased production of chemokines has also been demonstrated for other variants (11, 34, 36) .
The clinical impact and prognostic value of MYD88 mutations is variable among different lymphoproliferative disorders. Most likely this is due to the fact that the different cellular pathways affected by MYD88 mutation have different relevance for cell survival according to the stage of B-cell maturation, the genetic/epigenetic mechanisms involved in each type of tumor and the tumor cell interaction with the microenvironment.
Thus, CLL patients with mutated MYD88 show a favorable prognosis (35) . In DLBCL, MYD88 mutations have been related to specific extranodal sites (particularly the socalled immune-privileged territories) and might be associated with unfavorable outcome (37) . However, very few data are available in patients treated in the rituximab era with information on gene expression-COO and the different mutational variants of MYD88.
The aim of the present study was to assess the MYD88 mutational status in a series of patients with de novo DLBCL homogeneously treated with immunochemotherapy in a single institution in order to determine its relationship with initial clinical and biological features, including COO, as well as its impact on response to therapy and survival. Oncology Group (ECOG) scale, presence of B symptoms (fever, night sweats, weight loss) and bulky disease (defined as a tumor diameter >7 cm); blood cell counts; serum biochemistry, including lactate dehydrogenase (LDH) and β2-microglobulin (β2m) levels; chest, abdomen, and pelvis computerized tomography scans; PET/CT, and bone marrow biopsy. Post therapy re-staging consisted of a repetition of the abnormal previous tests and/or biopsies. Response was assessed according to conventional criteria (38) .
Main clinico-biological variables were recorded and analyzed according to MYD88 mutational status. In table 1, the main characteristics of patients are listed. All patients were treated in the rituximab era, although in 16 cases rituximab was discontinued mostly due to drug intolerance. Rituximab associated with cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) was administered to most patients (N=183, 87% The median follow-up for surviving patients was 6.0 years (range 0.78-12). Five-year progression free survival (PFS) of the series was 53% (95% CI: 46%-60%). Ninety-one patients eventually died during the follow-up, with a 5-year overall survival (OS) of 61% (95% CI: 54%-68%). PFS and OS curves are depicted in figure 1 Roncador (Centro Nacional de Investigaciones Oncologicas, Madrid, Spain) and MYC (clone Y69, Epitomics, USA). The conditions for all these antibodies and their evaluation were as previously described and followed the guidelines recommended by the Lunenburg Lymphoma Biomarker Consortium (39, 40) . The thresholds herein used for dichotomizing protein expression were based on these references and were as follows: MYC ≥40%; BCL2 ≥50%; BCL6 ≥50% and Ki67 index ≥80%. manufacturer's recommendations (DAKO). The cut-off values for the interphase FISH analyses were established following Ventura's criteria (42) . Tonsil sections were used as controls, and for each sample 100 to 200 evaluable nuclei with complete FISH signals were scored. For the break-apart probes, the cut-off values were 3% for the detection of the rearrangements and 6% to detect gains. For the dual fusion probe a cut-off of 11% for both structural and numerical abnormalities was considered (43) .
DNA extraction and assessment of MYD88 mutations DNA was isolated from frozen and paraffin tissue sections with the QIAamp DNA mini kit (Qiagen) according to the manufacturer's instructions. Screening for the most frequent MYD88 mutations (L265P, M232T, S219C, V217F and S222R) was performed using an allele-specific PCR assay achieved by Amplification Refractory Mutation System (ARMS®) technology (qBiomarker Somatic PCR Assay, Qiagen). This technique is based on the discrimination by Taqpolymerase between a match and a mismatch at the 3' end of a PCR primer. The method allows reproducible detection of MYD88 mutations in up to 1% of tumor DNA diluted in wild-type DNA. Cut-off for considering a case as mutated was Ct> 37. In MYD88 L265P cases, a relative quantitation analysis was done using the DLBCL ABC OCI Ly3 cell line as a calibrator.
Cell of origin assessment by gene expression based assay (GE-COO)
COO could be determined in 129 samples. In 60 cases, gene expression was assessed by using Affymetrix HG U133 plus 2.0 gene expression arrays as previously described (5, 10, 44) . All samples predicted as ABC DLBCL at higher than 90% were called ABC DLBCL. The samples that showed less than 10% of probability of being called ABC DLBCL were classified as GCB DLBCL. All the other cases were 
RESULTS

MYD88 mutations
MYD88 mutations were found in 47(22%) cases. The most frequent mutation was L265P detected in 39 cases (83% of mutated cases; 18.3% of the whole series) (table   2) . The other eight mutated cases corresponded to S219C and M232F mutations (four cases each). Two tumors showed a double mutation status: L265P/S219C and L265P/M232F and were considered part of the L265P group. No V217F or S222R mutations were observed in the present series.
MYD88 mutations in DLBCL subtypes
The clinical and biological characteristics of the DLBCL cases according to the mutational status of MYD88 are shown in table 2. The distribution according to GE-COO was as follows: 61 cases (47%) were assigned to GCB type and 54 (42%) to ABC type, whereas 14 (11%) remained unclassified. Among these 129 cases with available information on GE-COO, 32 tumors (25%) carried MYD88 mutations. As expected, MYD88 mutations were more frequently found in ABC-DLBCL subtype (N=22, 69%) but were also detected in 8 GCB subtype (25%) and 2 (6%) unclassified.
Interestingly L265P mutation was significantly more frequent in ABC than in GCB-DLBCL (82% vs.18%, respectively; p=0.0003). No significant relationship between the other mutations and GCB or ABC DLBCL subtypes was observed. S219C/M232F mutations (N=8) were detected in 4 ABC DLBCL and 4 GCB DLBC patients with no differences in the type of mutation (two S219C and two M232F cases in both subtypes).
We analyzed the allelic burden according to the COO only in the MYD88 L265P cases due to the lack of calibrator in the other mutations. The frequency for the mutant allele 
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MYD88 mutational status, cytokine expression and serum cytokines levels NF-κB signaling activation due to MYD88 mutation ends up with IL-6, IL-10 and interferon-β secretion. Thus, MYD88 mutational status was correlated with tumor expression of IL6, IL10, TNFα and IL1β with no significant associations (supplemental material table 2). There were no differences according to MYD88 in IL6, IL2-R and TNF serum levels (supplemental material table 3).
Clinical impact of MYD88 mutational status
Main clinical features of all DLBCL patients according to the MYD88 mutational status are listed in table 3. Patients with MYD88 L265P were older, had higher serum LDH levels and had more frequently extranodal involvement, particularly testis and breast.
MYD88 mutation was observed in only one out of 23 patients with gastro-intestinal involvement. No significant differences were observed in terms of specific location of disease or survival when only non-MYC/BCL2 co-expression cases were considered.
On the contrary, patients with MYD88 mutations other than L265P showed a trend for exclusive nodal disease (exclusive nodal involvement: 31%, 49% and 63% for MYD88 L265P, MYD88 wild type and MDY88 other than L265P, respectively; p=0.06). Ninety-one patients died after a median follow up of 6.0 years, including 67 of 166 (40%) with MYD88 wild type, 22/39 (56%) MYD88 L265P (56%) and 2/8 (25%) MYD88 other than L265P. Five-year OS was 62% (95% CI: 55%-70%), 52% (95% CI: 36%-68%) and 75% (95% CI: 45%-100%), respectively (p=0.05) ( figure 3A ). In the 39 cases carrying the L265P mutation, the presence of mutation at low tumor burden maintained (11) is the most frequent genetic alteration found in ABC DLBCLs and is associated with a poor outcome (27, 37) . The identification and characterization of the molecular basis of the dismal prognosis of patients with MYD88 mutant DLBCL could provide the rationale for new treatment targets in the involved pathways. Thus, MYD88 could emerge as a key biomarker in ABC DLBCL (23, 25, (47) (48) (49) .
We observed MYD88 mutations in 22% of the whole series, being L265P the most frequent one (39 of 47 cases, 83%). These figures are similar to previously reported studies ranging from 14% to 39% (11, 23, 50) , but higher than others (around 10%) (24, 25, 27, 37) , which may be due to the technique used. Next generation sequencing (NGS) techniques at low coverage are probably less sensitive than allele specific PCR.
Whether or not the presence of mutations at lower burden has prognostic impact is of high clinical interest. It is of note that in the present series the clinical impact of MYD88 mutation was maintained even at low allelic burden while with ARMS® technology we can detect less than 1% of tumor cells. 
While in most of the previous reports the different MYD88 mutations are considered as a whole to assess their clinical impact, we herein have shown that the type of mutation could be relevant. As previously described, patients with a MYD88 L265P mutation are older, mostly of ABC COO, have extranodal involvement, high serum LDH and high Ki67 index and a poorer OS (table 3 and figure 3) (27, 37, 50) . On the other hand, DLBCLs with MYD88 mutations other than L265P have no COO preference, are typically nodal and the OS is even better than that of MYD88 wild type. However, this information is based on a small number of patients and therefore should be confirmed in further studies. Even though the favorable prognosis of MYD88 mutations different from L265P could be hampered by the low number of patients, our data clearly show that such patients had a considerable better outcome than patients with MYD88 L265P.
Moreover, some biological data can support this different behavior: in a GCB DLBCL cell line with little endogenous NF-κB, Ngo et al. demonstrated that wild type MYD88 only modestly activated NF-κB, whereas L265P had the strongest NF-κB activation.
Other isoforms, including S219C, M232T, V217F and S222R, showed much less capacity to activate NF-κB than L265P (11) . This circumstance could explain the favorable evolution of some MYD88 mutated GCB-DLBCL cases. Patients with MYD88 L265P showed poor PFS and OS. This may be due to other related variables such as older age or ABC subtype rather than to the mutation itself. Similarly to previous data, in our series MYD88 L265P and IPI were independent variables to predict OS (37) .
However, when including GE-COO in the model, MYD88 L265P lost its prognostic significance at the multivariate level most likely because the vast majority of MYD88 mutated cases were of ABC origin. Interestingly, on the other hand, the co-expression of MYC and BCL2, typically observed in ABC DLBCLs and considered one of the factors of the adverse outcome in this group (51, 52) , was less frequently seen in our patients with MYD88 L265P than in wild type ones (18 vs. 41% respectively).
Moreover, patients with MYD88 mutation were significantly older than those without the mutation. This is consistent with the higher rate of these mutations in ABC DLBCL and the high frequency of this subtype in older patients (53) . As described in other series, patients with MYD88 L265P frequently had extranodal involvement, including bone marrow, testes and breast. Primary central nervous system was not evaluable in the present series since those patients were excluded from the study. It is of note that we did not find especial predilection for gastrointestinal system as previously suggested by others (37, 49, 50) . In summary, MYD88 mutational status analysis by PCR could help to recognize subgroups of patients with particular features and outcome. The current data highly suggests that MYD88 L265P mutation highlights a subpopulation of older patients with an ABC origin, specific extranodal involvement and unfavorable prognosis. On the contrary, MYD88 mutations other than L265P, also present in the elderly population, may have a favorable outcome. Due to the low incidence of these mutations, current data should be validated in further studies.
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